scholarly journals Prognostic value of gastric cancer-associated gene signatures: Evidence based on a meta-analysis using integrated bioinformatics methods

2018 ◽  
Vol 22 (11) ◽  
pp. 5743-5747 ◽  
Author(s):  
Jun Wang ◽  
Peng Gao ◽  
Yongxi Song ◽  
Jingxu Sun ◽  
Xiaowan Chen ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Evidence Based ◽  
Gene Signatures

scholarly journals Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Gastric Cancer: A Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Ye Qiu ◽  
Zongxin Zhang ◽  
Ying Chen
Keyword(s):  
Gastric Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Positive Lymph Node ◽  
Node Metastasis ◽  
Advanced Tumor ◽  
Tumor Node Metastasis Stage ◽  
Immune Inflammation

BackgroundPrevious studies have investigated the role of systemic immune-inflammation index (SII) as a prognostic factor for gastric cancer (GC) patients, although with inconsistent results. Thus, the aim of this study was to identify the prognostic value of SII in GC through meta-analysis.MethodsWe systematically searched the PubMed, Embase, and Web of Science databases for relevant studies investigating the prognostic role of SII in GC up to December 2019. The hazard ratios (HRs) and 95% confidence intervals (CIs) related to overall survival (OS) and disease-free survival (DFS) were combined. Odds ratios (ORs) and 95% CIs were pooled to assess the correlation between SII and clinicopathological features of GC.ResultsA total of eight studies, comprising 4,236 patients, were included in this meta-analysis. Pooled analysis indicated that a high pretreatment SII predicted poor OS (HR=1.40, 95% CI=1.08–1.81, p=0.010) but not poor DFS (HR=1.30, 95% CI=0.92–1.83, p=0.140) in GC. In addition, an elevated SII correlated with an advanced tumor–node–metastasis stage (OR=2.34, 95% CI=1.40–3.92, p=0.001), T3–T4 stage (OR=2.25, 95% CI=1.34–3.77, p=0.002), positive lymph node metastasis (OR=1.79, 95% CI=1.12–2.87, p=0.016), and tumor size ≥ 5 cm (OR=2.28, 95% CI=1.62–3.22, p<0.001) in patients with GC.ConclusionsA high pretreatment SII significantly associated with poorer survival outcomes as well as several clinical characteristics in GC. We suggest that SII could be monitored to guide prognostication and provide reliable information on the risk of disease progression in GC.

Prognostic value of epidermal growth factor receptor in patients with gastric cancer: A meta-analysis

Gene ◽  
2013 ◽  
Vol 529 (1) ◽  
pp. 69-72 ◽  
Author(s):  
Liu Hong ◽  
Yu Han ◽  
Jianjun Yang ◽  
Hongwei Zhang ◽  
Yan Jin ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Growth Factor Receptor ◽  
Epidermal Growth

scholarly journals Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis

2015 ◽  
Vol 9 (4) ◽  
pp. 1393-1400 ◽  
Author(s):  
PENG SONG ◽  
QIN YIN ◽  
MING LU ◽  
BO FU ◽  
BAOLIN WANG ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Value ◽  
Excision Repair ◽  
Meta Analysis ◽  
Complementation Group ◽  
Group 1

scholarly journals Prognostic value of long noncoding RNAs in gastric cancer: a meta-analysis

2018 ◽  
Vol Volume 11 ◽  
pp. 4877-4891 ◽  
Author(s):  
Song Gao ◽  
Zhi-Ying Zhao ◽  
Rong Wu ◽  
Yue Zhang ◽  
Zhen-Yong Zhang
Keyword(s):  
Gastric Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas

The prognostic value of pSTAT3 in gastric cancer: a meta-analysis

2015 ◽  
Vol 142 (3) ◽  
pp. 649-657 ◽  
Author(s):  
S. Yu ◽  
G. Li ◽  
Z. Wang ◽  
Z. Wang ◽  
C. Chen ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Value ◽  
Meta Analysis

The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis

Tumor Biology ◽  
2014 ◽  
Vol 35 (9) ◽  
pp. 8721-8731 ◽  
Author(s):  
Kong-Kong Wei ◽  
Lei Jiang ◽  
Yao-Yao Wei ◽  
Yu-Feng Wang ◽  
Xuan-Kun Qian ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Platinum Based Chemotherapy ◽  
Ercc1 Expression ◽  
Gastric Cancer Patients

scholarly journals Identification of MATN3 as a Novel Prognostic Biomarker for Gastric Cancer through Comprehensive TCGA and GEO Data Mining

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Pan Wang ◽  
Wei-sheng Xiao ◽  
Yue-hua Li ◽  
Xiao-ping Wu ◽  
Hong-bo Zhu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Poor Prognosis ◽  
Prognostic Value ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Free Survival ◽  
The World ◽  
Diagnostic And Prognostic Value

Gastric cancer (GC) is still a vital malignant cancer across the world with unsatisfactory prognostic results. Matrilin-3 (MATN3) is a member of the extracellular matrix (ECM) protein family. The present research intends to explore the expression level of MATN3 in patients with GC and to explore the prognosis significance of MATN3. In this study, we observed that the MATN3 expression was remarkably upregulated in GC samples in contrast to noncancer samples. Clinical analyses unveiled that high MATN3 expression was related to age, tumor status, and clinical stages. Survival analyses unveiled that patients with high MATN3 expression displayed a poorer overall survival and progression-free survival than those with low MATN3 expression. The AUC of the relevant ROC curve for 1 year, 3 years, and 5 years of survival is 0.571, 0.596, and 0.720, separately. Multivariate assays revealed that MATN3 expression and stage were independent predictors of poor prognosis of GC patients. A meta-analysis unveiled that high MATN3 expression was tightly associated with better overall survival. Overall, our data indicated that MATN3 may have a diagnostic and prognostic value for patients with advanced gastric cancer and assist to improve clinical outcomes for GC patients.

Sign in / Sign up

Export Citation Format

Share Document